247 related articles for article (PubMed ID: 37945750)
1. Acquired copy number variation in prostate tumours: a review of common somatic copy number alterations, how they are formed and their clinical utility.
O'Malley DE; Raspin K; Melton PE; Burdon KP; Dickinson JL; FitzGerald LM
Br J Cancer; 2024 Feb; 130(3):347-357. PubMed ID: 37945750
[TBL] [Abstract][Full Text] [Related]
2. Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race and are associated with survival.
Chen Y; Sadasivan SM; She R; Datta I; Taneja K; Chitale D; Gupta N; Davis MB; Newman LA; Rogers CG; Paris PL; Li J; Rybicki BA; Levin AM
BMC Med Genomics; 2020 Aug; 13(1):116. PubMed ID: 32819446
[TBL] [Abstract][Full Text] [Related]
3. The landscape of somatic chromosomal copy number aberrations in GEM models of prostate carcinoma.
Bianchi-Frias D; Hernandez SA; Coleman R; Wu H; Nelson PS
Mol Cancer Res; 2015 Feb; 13(2):339-47. PubMed ID: 25298407
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of intratumoural heterogeneity of somatic copy number alterations in diffuse glioma reveals clonality-dependent prognostic patterns.
Luo S; Zhang Y; Jia Y; Zhang X
Neuropathol Appl Neurobiol; 2022 Oct; 48(6):e12831. PubMed ID: 35767937
[TBL] [Abstract][Full Text] [Related]
5. Low-cost and clinically applicable copy number profiling using repeat DNA.
Abujudeh S; Zeki SS; van Lanschot MCJ; Pusung M; Weaver JMJ; Li X; Noorani A; Metz AJ; Bornschein J; Bower L; Miremadi A; Fitzgerald RC; Morrissey ER; Lynch AG
BMC Genomics; 2022 Aug; 23(1):599. PubMed ID: 35978291
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide association study of germline copy number variations reveals an association with prostate cancer aggressiveness.
Brezina S; Feigl M; Gumpenberger T; Staudinger R; Baierl A; Gsur A
Mutagenesis; 2020 Jul; 35(3):283-290. PubMed ID: 32255470
[TBL] [Abstract][Full Text] [Related]
7. Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data.
Camacho N; Van Loo P; Edwards S; Kay JD; Matthews L; Haase K; Clark J; Dennis N; Thomas S; Kremeyer B; Zamora J; Butler AP; Gundem G; Merson S; Luxton H; Hawkins S; Ghori M; Marsden L; Lambert A; Karaszi K; Pelvender G; Massie CE; Kote-Jarai Z; Raine K; Jones D; Howat WJ; Hazell S; Livni N; Fisher C; Ogden C; Kumar P; Thompson A; Nicol D; Mayer E; Dudderidge T; Yu Y; Zhang H; Shah NC; Gnanapragasam VJ; ; Isaacs W; Visakorpi T; Hamdy F; Berney D; Verrill C; Warren AY; Wedge DC; Lynch AG; Foster CS; Lu YJ; Bova GS; Whitaker HC; McDermott U; Neal DE; Eeles R; Cooper CS; Brewer DS
PLoS Genet; 2017 Sep; 13(9):e1007001. PubMed ID: 28945760
[TBL] [Abstract][Full Text] [Related]
8. Estimating copy number to determine BRCA2 deletion status and to expect prognosis in localized prostate cancer.
Nukaya T; Sumitomo M; Sugihara E; Takeda M; Nohara S; Tanishima S; Takenaka M; Zennami K; Takahara K; Shiroki R; Saya H
Cancer Med; 2023 Apr; 12(7):8154-8165. PubMed ID: 36645189
[TBL] [Abstract][Full Text] [Related]
9. High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers.
Castro E; Jugurnauth-Little S; Karlsson Q; Al-Shahrour F; Piñeiro-Yañez E; Van de Poll F; Leongamornlert D; Dadaev T; Govindasami K; Guy M; Eeles R; Kote-Jarai Z;
Ann Oncol; 2015 Nov; 26(11):2293-300. PubMed ID: 26347108
[TBL] [Abstract][Full Text] [Related]
10. The role of genetic markers in the management of prostate cancer.
Choudhury AD; Eeles R; Freedland SJ; Isaacs WB; Pomerantz MM; Schalken JA; Tammela TL; Visakorpi T
Eur Urol; 2012 Oct; 62(4):577-87. PubMed ID: 22695242
[TBL] [Abstract][Full Text] [Related]
11. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers.
Lozano R; Castro E; Lopez-Campos F; Thorne H; Ramirez-Backhaus M; Aragon IM; Cendón-Florez Y; Gutierrez-Pecharroman A; Salles DC; Romero-Laorden N; Lorente D; González-Peramato P; Calatrava A; Alonso C; Anido U; Arévalo-Lobera S; Balmaña J; Chirivella I; Juan-Fita MJ; Llort G; Y Cajal TR; Almagro E; Alameda D; López-Casas PP; Herrera B; Mateo J; Pritchard CC; Antonarakis ES; Lotan TL; Rubio-Briones J; Sandhu S; Olmos D
Eur J Cancer; 2023 May; 185():105-118. PubMed ID: 36972661
[TBL] [Abstract][Full Text] [Related]
12. Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer.
Adamson AW; Ding YC; Steele L; Leong LA; Morgan R; Wakabayashi MT; Han ES; Dellinger TH; Lin PS; Hakim AA; Wilczynski S; Warden CD; Tao S; Bedell V; Cristea MC; Neuhausen SL
J Ovarian Res; 2023 Jul; 16(1):141. PubMed ID: 37460928
[TBL] [Abstract][Full Text] [Related]
13. Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression.
Roszik J; Wu CJ; Siroy AE; Lazar AJ; Davies MA; Woodman SE; Kwong LN
Sci Rep; 2016 Jan; 6():19649. PubMed ID: 26787600
[TBL] [Abstract][Full Text] [Related]
14. Somatic copy number alterations are predictive of progression-free survival in patients with lung adenocarcinoma undergoing radiotherapy.
Kou F; Wu L; Guo Y; Zhang B; Li B; Huang Z; Ren X; Yang L
Cancer Biol Med; 2021 Aug; 19(5):685-95. PubMed ID: 34448554
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and performance of a novel probe panel to detect somatic DNA copy number alterations in clinical specimens for predicting prostate cancer progression.
Liu W; Hou J; Petkewicz J; Na R; Wang CH; Sun J; Gallagher J; Bogachkov YY; Swenson L; Regner M; Resurreccion WK; Isaacs WB; Brendler CB; Crawford S; Zheng SL; Helfand BT; Xu J
Prostate; 2020 Oct; 80(14):1253-1262. PubMed ID: 32803894
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous Copy Number Alteration and Single-Nucleotide Variation Analysis in Matched Aqueous Humor and Tumor Samples in Children with Retinoblastoma.
Schmidt MJ; Prabakar RK; Pike S; Yellapantula V; Peng CC; Kuhn P; Hicks J; Xu L; Berry JL
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239954
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of copy number alterations and clinical progression across advanced prostate cancer.
Grist E; Friedrich S; Brawley C; Mendes L; Parry M; Ali A; Haran A; Hoyle A; Gilson C; Lall S; Zakka L; Bautista C; Landless A; Nowakowska K; Wingate A; Wetterskog D; Hasan AMM; Akato NB; Richmond M; Ishaq S; Matthews N; Hamid AA; Sweeney CJ; Sydes MR; Berney DM; Lise S; ; Parmar MKB; Clarke NW; James ND; Cremaschi P; Brown LC; Attard G
Genome Med; 2022 Sep; 14(1):102. PubMed ID: 36059000
[TBL] [Abstract][Full Text] [Related]
18. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study.
Ross-Adams H; Lamb AD; Dunning MJ; Halim S; Lindberg J; Massie CM; Egevad LA; Russell R; Ramos-Montoya A; Vowler SL; Sharma NL; Kay J; Whitaker H; Clark J; Hurst R; Gnanapragasam VJ; Shah NC; Warren AY; Cooper CS; Lynch AG; Stark R; Mills IG; Grönberg H; Neal DE;
EBioMedicine; 2015 Sep; 2(9):1133-44. PubMed ID: 26501111
[TBL] [Abstract][Full Text] [Related]
19. Genetically predicted telomere length is associated with clonal somatic copy number alterations in peripheral leukocytes.
Brown DW; Lin SH; Loh PR; Chanock SJ; Savage SA; Machiela MJ
PLoS Genet; 2020 Oct; 16(10):e1009078. PubMed ID: 33090998
[TBL] [Abstract][Full Text] [Related]
20. Pan-cancer patterns of somatic copy number alteration.
Zack TI; Schumacher SE; Carter SL; Cherniack AD; Saksena G; Tabak B; Lawrence MS; Zhsng CZ; Wala J; Mermel CH; Sougnez C; Gabriel SB; Hernandez B; Shen H; Laird PW; Getz G; Meyerson M; Beroukhim R
Nat Genet; 2013 Oct; 45(10):1134-40. PubMed ID: 24071852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
